Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GALR3 | O60755 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150293 | 0.83 | DGAT1 (1.00) | DGAT1KDM4EGLACES2CASP1 | |
| Hydrochloric Acid SCHEMBL26618126 | 0.82 | DGAT1 (0.96) | DGAT1KDM4EGLACES2CASP1 | |
| SCHEMBL30722862 | 0.81 | KDM4E (0.59) | DGAT1KDM4EGLACES2CASP1 | |
| SCHEMBL2554 | 0.81 | KDM4E (0.59) | DGAT1KDM4EGLACES2CASP1 | |
| SCHEMBL2344362 | 0.80 | DGAT1 (0.67) | DGAT1KDM4EGLACES2CASP1 | |
| SCHEMBL181200 | 0.79 | ALDH1A1 (0.52) | DGAT1KDM4EGLACES2CASP1 | |
| SCHEMBL30374539 | 0.79 | DGAT1 (0.50) | DGAT1KDM4EGLACES2CASP1 | |
| SCHEMBL29401981 | 0.79 | ALDH1A1 (0.52) | DGAT1KDM4EGLACES2CASP1 | |
| SCHEMBL10082 | 0.79 | DGAT1 (0.50) | DGAT1KDM4EGLACES2CASP1 | |
| SCHEMBL16079251 | 0.79 | DGAT1 (0.50) | DGAT1KDM4EGLACES2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744305-A | Synthesis method of 2,4-dichloro-3-cyan-5-fluorobenzoic acid | ZHEJIANG ZHONGXIN CHEMICALS CO LTD | 2015-07-01 | — | — | CN | claimed |
| CN-1333698-A | Combination chemotherapy | WARNER LAMBERT CO (US) | 2002-01-30 | — | — | CN | claimed |
| US-20260060985-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4594308-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | Vividion Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12377102-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | GALECTIN SCIENCES, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024073587-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-111032039-B | Compounds for the prevention and treatment of medical disorders and uses thereof | 卡莱克汀科学有限责任公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230116370-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | GALECTIN SCIENCES, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| CN-112279810-B | 6-oxo-5, 6-dihydrophenanthridine-4-formamide compound, preparation method, pharmaceutical composition and application | 北京华氏开元医药科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| WO-2007065655-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NEUROSEARCH SWEDEN AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| CN-1333698-A | Combination chemotherapy | WARNER LAMBERT CO (US) | 2002-01-30 | — | — | CN | disclosed |
| US-6300352-B1 | FOR THERAPY OF ASTHMA | ASTRAZENECA AB (SE) | 2001-10-09 | — | — | US | disclosed |
| CN-1257481-A | Pyridine derivatives and pharmaceutical compositions containing them | ASTRA PHARMA PROD (GB) | 2000-06-21 | — | — | CN | disclosed |
| EP-0971892-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astra Pharmaceuticals Limited (GB) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042670-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, MMP10 | DGAT1 3383/4885KDM4E 1834/4885GLA 526/4885 |
| US-20260060985-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS3, LGALS1, LGALS2 | DGAT1 2402/4885KDM4E 4183/4885GLA 308/4885 |
| US-20230116370-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS1, LGALS2, LGALS3 | DGAT1 2101/4885KDM4E 4622/4885GLA 61/4885 |
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | LGALS1, LGALS2, LGALS3 | DGAT1 2101/4885KDM4E 4622/4885GLA 61/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | DGAT1 1939/4885KDM4E 1830/4885GLA 2825/4885 |
| US-12377102-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | LGALS1, LGALS2, LGALS3 | DGAT1 2101/4885KDM4E 4622/4885GLA 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.